FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
64 letters match. Newest first.
-
DrugsNanjing Hanxin Pharmaceutical Technology Co. Ltd.
FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.
High risk -
DrugsRonanRx, Inc. dba RonanRx
FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsPine Pharmaceuticals, LLC
FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.
High risk -
AnimalStokes Healthcare Inc. dba Epicur Pharma
FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.
High risk -
DrugsKetamine Troche Store / www.ketaminetrochestore.com
FDA warned online seller Ketamine Troche Store that its website sells unapproved, misbranded ketamine drugs without prescriptions.
High risk -
DrugsBuy Keta Online / www.buyketaonline.com
FDA warns Buy Keta Online that its website sells unapproved and misbranded ketamine drugs to U.S. consumers.
High risk -
DrugsKetamine Store / www.ketaminestore.org
FDA warned website Ketamine Store for selling unapproved, misbranded ketamine liquid and compounded products online without prescriptions.
High risk -
DrugsNativeMed LLC dba NativeMed
FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsNexus Health Solutions LLC dba Harper Meds
FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Low -
DrugsGlow Medispa, LLC dba Mint Med
FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.
Low -
DrugsD&H Medical Services
FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.
Low -
DrugsMedica Weight Loss
FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.
Medium -
DrugsOrderlyMeds LLC dba OrderlyMeds
FDA warned OrderlyMeds over website claims for compounded semaglutide and tirzepatide, saying its labels and 'FDA-licensed pharmacy' claim are misleading.
Low -
DrugsJoi and Blokes dba Joi + Blokes
FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.
Medium -
DrugsClover Meds LLC dba Clover Meds
Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.
Medium -
DrugsFagron BV
FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.
High risk -
DrugsProRx LLC
ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.
High risk -
DrugsApothecary Pharma, LLC
FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.
High risk -
DrugsRefills Health, LLC dba Refills Health
FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.
Medium -
DrugsWeightless Medical LLC dba WeightCare
FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.
Low -
DrugsViv Health, Inc. dba VIV RX
FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsIvim Services LLC dba Ivim
FDA says Ivim's telehealth website mislabels compounded semaglutide and tirzepatide as Ivim-made when it is not the compounder.
Low -
DrugsMaxLife Technologies Inc. dba Maxlife
FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.
Medium -
DrugsBetter Health Labs, Inc. dba Measured
FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.
Medium -
DrugsMEDVi, LLC dba MEDVi
FDA says telehealth seller MEDVi misbranded compounded semaglutide and tirzepatide by implying MEDVi makes them and that they are FDA-approved.
Medium -
DrugsNewman Clinic, PLLC dba Newman Clinic
FDA told Newman Clinic its website misbranded compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsBliv Wellness LLC dba Bliv
FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsGenoGenix LLC
FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.
High risk -
DrugsMedisourceRx
MedisourceRx failed to report a serious adverse event and had inadequate procedures, so its compounded drugs lost legal exemptions.
Medium -
DrugsPQ Pharmacy, LLC
FDA warns PQ Pharmacy, a Florida sterile drug compounder, that its products were made under unsafe conditions.
High risk -
DrugsTurbare Manufacturing
FDA warns outsourcing facility Turbare Manufacturing of Conway, Arkansas, for making sterile drugs under insanitary conditions.
High risk -
DrugsWells Pharma of Houston, LLC
FDA warns Wells Pharma of Houston over sterile compounded drugs made under insanitary conditions.
High risk -
DrugsAmazing Meds
FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.
High risk -
DrugsGenLabMeds
GenLabMeds offered compounded retatrutide, semaglutide and tirzepatide online as unapproved, misbranded drugs with false or misleading claims.
High risk -
DrugsMedClub by Dr. Jenn
FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.
High risk -
DrugsGLP-1 Solution
GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.
High risk -
DrugsASN-LABS
ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.
High risk -
DrugsEA WORKS Limited Liability Company dba Trust Labs
FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.
High risk -
DrugsChromatography Institute of America dba Compounder’s International Analytical Laboratory
FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.
High risk -
DrugsExela Pharma Sciences, LLC
Exela Pharma Sciences failed CGMP (current good manufacturing practice) for sterile injectable drugs, including invalidated sterility-media tests and inaccurate microbiology records.
High risk -
DrugsStaska Pharmaceuticals, Inc.
FDA warns Staska Pharmaceuticals, a Nebraska outsourcing facility, that sterile compounded drugs had contamination risks and labeling problems.
High risk -
DrugsOSRX, Inc.
OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.
High risk -
DrugsTailstorm Health Inc. dba Medivant Health
Tailstorm Health (Medivant Health) sterile compounded drugs had insanitary conditions and current good manufacturing practice failures, prompting a bevacizumab recall.
High risk -
DrugsEmpower Clinic Services, LLC dba Empower Pharma
FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.
High risk -
DrugsAnnovex Pharma, Inc.
FDA warns outsourcing facility Annovex Pharma in Lorton, VA, over contaminated sterile drug production and missed FDA reports.
High risk -
DrugsRight Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals
FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.
High risk -
DrugsProRx, LLC
FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.
High risk -
DrugsFagron Compounding Services, LLC dba Fagron Sterile Service
FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.
High risk -
DrugsStokes Healthcare Inc. dba Epicur Pharma
Sterile compounding facility Epicur Pharma made drugs under insanitary conditions and with serious quality failures, FDA says.
High risk -
DrugsCentral Admixture Pharmacy Services, Inc.
FDA warns Central Admixture Pharmacy Services over sterile compounded drugs, contamination risks, and quality failures at its San Diego site.
High risk